Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.
Sihuan Pharmaceutical Holdings Group Ltd. announced that its innovative drug, Bireociclib Tablets (brand name: Xuanyuening), developed by its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been included in the National Reimbursement Drug List (NRDL) for 2025. This inclusion is expected to enhance the drug’s affordability and accessibility, significantly impacting Xuanzhu Biopharm’s market presence and sales. Bireociclib, a novel CDK2/4/6 inhibitor, offers advantages in treating advanced or metastatic breast cancer with reduced toxicity. The drug’s inclusion in the NRDL is anticipated to bolster Xuanzhu Biopharm’s long-term business development and market expansion efforts.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd., founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is an international medical aesthetic and pharmaceutical company. It focuses on innovation with a robust research and development platform, a diverse global product pipeline, and a comprehensive production and sales system. The company aims to be a leader in medical aesthetics and biopharmaceuticals in China, driven by its strategic focus on these sectors.
YTD Price Performance: 103.05%
Average Trading Volume: 44,226,805
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.41B
Learn more about 0460 stock on TipRanks’ Stock Analysis page.